Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities.

Cancer Cell Biology Health Sciences High Throughput Screening Organoids Stem Cells

Journal

STAR protocols
ISSN: 2666-1667
Titre abrégé: STAR Protoc
Pays: United States
ID NLM: 101769501

Informations de publication

Date de publication:
18 03 2022
Historique:
entrez: 17 1 2022
pubmed: 18 1 2022
medline: 9 4 2022
Statut: epublish

Résumé

Patient-derived tumor organoids can be predictive of patient's treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for organoid drug screening using, as proof-of-principle, patient-derived malignant rhabdoid tumor organoids. The protocol can be adapted for drug testing on any tumor and/or normal tissue-derived organoid culture. For complete details on the use and execution of this protocol, please refer to Calandrini et al. (2021).

Identifiants

pubmed: 35036959
doi: 10.1016/j.xpro.2021.101079
pii: S2666-1667(21)00785-1
pmc: PMC8752949
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101079

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Nat Biotechnol. 2019 Mar;37(3):303-313
pubmed: 30833775
Nat Commun. 2020 Mar 11;11(1):1310
pubmed: 32161258
Cell Rep. 2020 May 5;31(5):107588
pubmed: 32375033
Cancer Cell. 2021 Sep 13;39(9):1190-1201
pubmed: 34416168
Nature. 2015 May 7;521(7550):43-7
pubmed: 25924068
Nat Rev Urol. 2020 Jun;17(6):311-313
pubmed: 32242130
Nat Commun. 2019 Sep 5;10(1):3991
pubmed: 31488816
Mod Pathol. 2006 May;19(5):717-25
pubmed: 16528370
Cell Rep. 2021 Aug 24;36(8):109568
pubmed: 34433038
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26580-26590
pubmed: 31818951
Am J Surg Pathol. 2004 May;28(5):644-50
pubmed: 15105654
Nat Commun. 2021 Mar 3;12(1):1407
pubmed: 33658498
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Nat Commun. 2021 Jun 23;12(1):3896
pubmed: 34162837

Auteurs

Camilla Calandrini (C)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Oncode Institute, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.

Jarno Drost (J)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Oncode Institute, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH